Videos

Panelists discuss how radiation oncologists can increase pulmonologist awareness about radiation therapy through multidisciplinary collaboration, educating colleagues about modern treatment capabilities, engaging them in fiducial placement and toxicity management, and positioning radiation oncology as both an upstream and downstream service that can help solve pulmonologists’ clinical challenges.

Experts discuss the feasibility and safety of outpatient bispecific antibody treatment for multiple myeloma, emphasizing the importance of careful patient selection, robust support systems, and multidisciplinary collaboration to manage potential complications such as cytokine release syndrome (CRS) and ensure timely care, highlighting that with these measures, outpatient administration can safely expand access while maintaining efficacy and patient convenience.

Those with cancer may be able to get cellular therapies more affordably if countries and health systems adopt decentralized closed-system manufacturing.

Experts discuss the growing role of time-limited Bruton tyrosine kinase (BTK) inhibitor plus venetoclax therapy for high-risk chronic lymphocytic leukemia (CLL)—particularly in patients with deletion 17p—emphasizing the SEQUOIA R&D data that support flexible, minimal residual disease (MRD)-guided treatment durations and all-oral regimens as effective, convenient, and patient-centered options for achieving deep, durable responses.

Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.

The use of enhanced imaging and adaptive radiotherapy has lessened the burden on patients with cancer receiving radiotherapy as treatment.

Panelists discuss how to approach case-based treatment decisions in patients with lower-risk MDS, examining a 77-year-old man with symptomatic anemia (hemoglobin, 7.6 g/dL; EPO,  > 200 mU/mL; SF3B1-negative) who would benefit from luspatercept but faces insurance barriers without transfusion dependence, and a 70-year-old woman for whom erythropoiesis-stimulating agent (ESA) therapy was not successful and who requires second-line treatment. The experts debate personalized approaches considering molecular features, patient goals, and the balance between luspatercept and imetelstat based on individual clinical characteristics.

Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.

Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.

Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.

Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.

Although data for bispecific antibodies are maturing, CAR T-cell therapy has longer-term data that show prolonged and durable efficacy in LBCL.

A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.

Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.

An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.

Experts discuss the significant advancement of outpatient and hybrid dosing strategies for bispecific antibodies such as teclistamab in multiple myeloma, highlighting that with careful patient selection, multidisciplinary support, and proactive monitoring, these approaches maintain efficacy and safety comparable to inpatient care while enhancing patient convenience and expanding access.

Experts discuss new real-world data supporting the safety and effectiveness of outpatient and hybrid step-up dosing of teclistamab in relapsed or refractory multiple myeloma, showing strong response rates, durable disease control, and manageable toxicity and reinforcing the feasibility of administering bispecific therapies beyond inpatient settings and expanding access in community care.

Experts discuss real-world evidence demonstrating that bispecific antibodies such as teclistamab can be safely and effectively administered in community oncology settings using hybrid care models, with robust outcomes even in non–trial-eligible patients and manageable safety profiles that support broader access beyond academic centers.

Experts discuss real-world data showing that teclistamab delivers efficacy and safety outcomes comparable to findings from clinical trials in patients with relapsed/refractory multiple myeloma—including older individuals at high risk—while highlighting the emerging role of shared care models to manage step-up dosing and expand access across community oncology settings.

Whereas CAR T-cell therapies need weeks to be engineered, bispecific therapies can be ready much quicker for patients with progressing non-Hodgkin lymphoma.

Panelists discuss how step-up dosing has successfully transitioned from inpatient-only to hybrid and outpatient models using prophylactic tocilizumab and standardized protocols for managing cytokine release syndrome.

Panelists discuss how talquetamab’s unique skin and taste toxicities are manageable through dose modifications and supportive care, with IVIG prophylaxis being crucial for BCMA-targeted but not necessarily GPRC5D-targeted therapies.

Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.

Panelists discuss how the LAURA trial demonstrated dramatic progression-free survival improvements with adjuvant osimertinib for EGFR-mutated stage III lung cancer, while the SINDAS, NORTHSTAR, and LONESTAR trials explore whether upfront local consolidative radiation therapy to oligometastatic sites can improve outcomes in both EGFR-mutated and nonmutated metastatic disease.

A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.

Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.

Experts discuss the promising results of a SEQUOIA trial substudy evaluating Bruton tyrosine kinase (BTK) inhibitor plus venetoclax combination therapy in patients with chronic lymphocytic leukemia (CLL)—including those with TP53 mutations or deletion 17p—highlighting high progression-free survival (PFS), deep minimal residual disease (MRD)-driven remissions, and strong safety outcomes that support this doublet as a flexible, effective frontline option for high-risk disease.

Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.

Panelists discuss how the timing of treatment initiation in lower-risk MDS (LR-MDS) should be approached. Team Whataburger advocates for earlier intervention based on symptoms and hemoglobin levels around 9 to 10 g/dL (citing European practices and the upcoming ULTIMATE study), while Team In-and-Out argues for delayed treatment until transfusion dependence develops to maximize the therapeutic lifespan of drugs such as luspatercept, given that symptomatically reported anemia can be subjective in this older population with multiple comorbidities.

Panelists discuss how to manage luspatercept “super responders” with hemoglobin levels above 12 g/dL, with Team Whataburger advocating for dose reduction to maintain stable responses and avoid hemoglobin fluctuations that disrupt patients’ quality of life, while Team In-and-Out argues for holding doses due to lack of safety data at very high hemoglobin levels and cost considerations. However, both teams acknowledge the need for individualized approaches and question whether current hemoglobin ceiling limits are appropriate for patients with MDS.